Monopar Therapeutics Inc
NASDAQ:MNPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Agrify Corp
NASDAQ:AGFY
|
US |
|
Supermax Corporation Bhd
OTC:SPMXF
|
MY |
|
H
|
HiteJinro Holdings Co Ltd
KRX:000140
|
KR |
|
Magna Mining Inc
XTSX:NICU
|
CA |
|
AP Rentals Holdings Ltd
HKEX:1496
|
HK |
|
Z
|
Zhejiang Wanfeng Chemical Co Ltd
SSE:603172
|
CN |
|
Telefonaktiebolaget LM Ericsson
STO:ERIC B
|
SE |
|
T
|
THK Co Ltd
TSE:6481
|
JP |
|
Kinepolis Group NV
XBRU:KIN
|
BE |
|
L
|
Le Lavoir Ltd
BSE:539814
|
IN |
|
Bharat Bijlee Ltd
BSE:503960
|
IN |
|
Coventry Group Ltd
ASX:CYG
|
AU |
|
Valid Solucoes SA
BOVESPA:VLID3
|
BR |
|
Wuxi Hyatech Co Ltd
SSE:688510
|
CN |
|
P
|
Petrolimex Joint Stock Tanker Co
VN:PJT
|
VN |
|
Z
|
Zhejiang Zomax Transmission Co Ltd
SSE:603767
|
CN |
Monopar Therapeutics Inc
Total Current Assets
Monopar Therapeutics Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
Total Current Assets
$140.5m
|
CAGR 3-Years
120%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$29.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$18.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$29.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$11.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$18B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
Monopar Therapeutics Inc
Glance View
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
See Also
What is Monopar Therapeutics Inc's Total Current Assets?
Total Current Assets
140.5m
USD
Based on the financial report for Dec 31, 2025, Monopar Therapeutics Inc's Total Current Assets amounts to 140.5m USD.
What is Monopar Therapeutics Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
53%
Over the last year, the Total Current Assets growth was 133%. The average annual Total Current Assets growth rates for Monopar Therapeutics Inc have been 120% over the past three years , 53% over the past five years .
